Home > > North America And Global Direct to Consumer Genetic Testing Market- Size, Share, Growth Rate, and Forecast
The North America Direct to Consumer Genetic Testing market was valued at $109,019.8 Million in 2023, and is projected to reach $135,139.1 Million by 2030 growing at a CAGR of 3.16% from 2024 to 2030. Clinical Chemistry segment is expected to be the highest contributor to this market, with $47,870.0 Million in 2023, and is anticipated to reach $59,026.8 by 2030, registering a CAGR of 3.09%. Medical Microbiology & Cytology segment is anticipated to reach $26,441.9 Million by 2030 with the highest CAGR of 3.25%. Clinical Chemistry and Human & Tumor Genetics segments collectively expected to account for about 67.5% share of the North America Direct to Consumer Genetic Testing market in 2023, with the former constituting around 43.9% share. Medical Microbiology & Cytology and Human & Tumor Genetics segments are expected to witness significant growth rates at a CAGR of 3.25% and 3.22% respectively, during the forecast period. Presently, share of these two segments is estimated to be around 43.0% in the overall North America Direct to Consumer Genetic Testing market in 2023, and is anticipated to reach 43.2% by 2030. Test Type Human & Tumor Genetics Clinical Chemistry Medical Microbiology & Cytology Other Test Types Service provider Hospital-based Laboratories Stand-alone Laboratories Clinic-based Laboratories BY REGION North America U.s. Canada Mexico Europe Germany France U.k. Italy Spain Russia Rest of Europe Asia China India Japan Australia Rest of Asia Middle East & Africa Brazil South Africa GCC Rest of MENA